Trial · NCT01114581
Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
NCT01114581, Phase 2, Completed, Reckitt Benckiser LLC; results first posted 2012-10-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection. Trials, record NCT01114581. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01114581
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
- NCT number
- NCT01114581
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 38 participants, actual
- Lead sponsor
- Reckitt Benckiser LLC
- Conditions
- Acute Respiratory Infection
- Interventions
- Mucinex, Placebo
- First posted
- 2010-05-03
- Last updated
- 2018-09-19
- Results first posted
- 2012-10-08
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs | 3 hours following inhalation of radioactive tracer particles | Percentage of inhaled radioactive tracer (Ave180Clear) |
| Secondary | Guaifenesin AUC(0-3) | 3 hours following dose administration | |
| Secondary | Assess Sputum Properties (Objective Measures) and Symptoms (Subjective Measures) After Treatment With Mucinex or Placebo. | Within 10 days of developing symptoms associated with a respiratory tract infection |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs | 3 hours following inhalation of radioactive tracer particles | Intent to treat | Percentage of inhaled radioactive tracer | MEAN |
| SECONDARY | Guaifenesin AUC(0-3) | 3 hours following dose administration | ng*hr/mL | GEOMETRIC_MEAN | |
| SECONDARY | Assess Sputum Properties (Objective Measures) and Symptoms (Subjective Measures) After Treatment With Mucinex or Placebo. | Within 10 days of developing symptoms associated with a respiratory tract infection | The data for this secondary outcome cannot be reported as operational issues with the collection and transport of the samples occurred. |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs | Guaifenesin | 21.4 | Standard Deviation 99 | Percentage of inhaled radioactive tracer | |
| Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs | Placebo | 23.1 | Standard Deviation 99 | Percentage of inhaled radioactive tracer | |
| Guaifenesin AUC(0-3) | Guaifenesin | 4060 | Geometric Coefficient of Variation 71 | ng*hr/mL |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Guaifenesin | 19 | |
| Overall Study | STARTED | Placebo | 19 | |
| Overall Study | COMPLETED | Guaifenesin | 19 | |
| Overall Study | COMPLETED | Placebo | 19 | |
| Overall Study | NOT COMPLETED | Guaifenesin | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Guaifenesin | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Guaifenesin | 0 | 19 |
| Total, other adverse events | Placebo | 0 | 19 |
| Total, serious adverse events | Guaifenesin | 0 | 19 |
| Total, serious adverse events | Placebo | 0 | 19 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26462765 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Guaifenesin vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01114581
GET https://conductscience.org/api/trials/v1/NCT01114581/registered